These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32702468)

  • 1. Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).
    Agbaje OF; Coleman RL; Hattersley AT; Jones AG; Pearson ER; Shields BM; Holman RR;
    Diabetes Res Clin Pract; 2020 Aug; 166():108333. PubMed ID: 32702468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
    BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
    Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
    BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
    Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
    Matthews DR; Cull CA; Stratton IM; Holman RR; Turner RC
    Diabet Med; 1998 Apr; 15(4):297-303. PubMed ID: 9585394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.
    Marre M; Howlett H; Lehert P; Allavoine T
    Diabet Med; 2002 Aug; 19(8):673-80. PubMed ID: 12147149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
    Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
    Adler AI; Coleman RL; Leal J; Whiteley WN; Clarke P; Holman RR
    Lancet; 2024 Jul; 404(10448):145-155. PubMed ID: 38772405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
    Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
    J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
    Panikar V; Chandalia HB; Joshi SR; Fafadia A; Santvana C
    J Assoc Physicians India; 2003 Nov; 51():1061-4. PubMed ID: 15260389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes.
    Matthews DR; Paldánius PM; Proot P; Foley JE; Stumvoll M; Del Prato S
    Diabet Med; 2019 Apr; 36(4):505-513. PubMed ID: 30576013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.